Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, BST W1540, Pittsburgh, PA 15261, USA.
Semin Immunol. 2011 Aug;23(4):252-63. doi: 10.1016/j.smim.2011.06.007. Epub 2011 Jul 7.
The pursuit of clinical transplant tolerance has led to enhanced understanding of mechanisms underlying immune regulation, including the characterization of immune regulatory cells, in particular antigen-presenting cells (APC) and regulatory T cells (Treg), that may play key roles in promoting operational tolerance. Dendritic cells (DC) are highly efficient APC that have been studied extensively in rodents and humans, and more recently in non-human primates. Owing to their ability to regulate both innate and adaptive immune responses, DC are considered to play crucial roles in directing the alloimmune response towards transplant tolerance or rejection. Mechanisms via which they can promote central and peripheral tolerance include clonal deletion, the induction of Treg, and inhibition of memory T cell responses. These properties have led to the use of tolerogenic DC as a therapeutic strategy to promote organ transplant tolerance. In rodents, infusion of donor- or recipient-derived tolerogenic DC can extensively prolong donor-specific allograft survival, in association with regulation of the host T cell response. In clinical transplantation, progress has been made in monitoring DC in relation to graft outcome, including studies in operational liver transplant tolerance. Although clinical trials involving immunotherapeutic DC for patients with cancer are ongoing, implementation of human DC therapy in clinical transplantation will require assessment of various critical issues. These include cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy. With ongoing non-human primate studies focused on DC therapy, these logistics can be investigated seeking the optimal approaches. The scientific rationale for implementation of tolerogenic DC therapy to promote clinical transplant tolerance is strong. Evaluation of technical and therapeutic logistic issues is an important next step prior to the application of tolerogenic DC in clinical organ transplantation.
对临床移植耐受的追求导致人们对免疫调节机制有了更深入的了解,包括对免疫调节细胞(尤其是抗原呈递细胞 (APC) 和调节性 T 细胞 (Treg))的特征的了解,这些细胞可能在促进操作性耐受方面发挥关键作用。树突状细胞 (DC) 是高效的 APC,在啮齿动物和人类中得到了广泛研究,最近在非人类灵长类动物中也得到了研究。由于其调节固有和适应性免疫反应的能力,DC 被认为在指导同种异体免疫反应向移植耐受或排斥方向发展方面发挥着至关重要的作用。它们可以促进中枢和外周耐受的机制包括克隆删除、诱导 Treg 和抑制记忆 T 细胞反应。这些特性导致使用耐受树突状细胞作为一种治疗策略来促进器官移植耐受。在啮齿动物中,输注供体或受者来源的耐受树突状细胞可以广泛延长供体特异性同种异体移植物的存活时间,并与宿主 T 细胞反应的调节有关。在临床移植中,已经在与移植物结果相关的方面监测 DC 方面取得了进展,包括在操作性肝移植耐受方面的研究。尽管正在进行涉及癌症患者免疫治疗性 DC 的临床试验,但在临床移植中实施人类 DC 治疗将需要评估各种关键问题。这些问题包括细胞分离和纯化技术、来源、给药途径和时间以及联合免疫抑制治疗。随着针对 DC 治疗的非人类灵长类动物研究的不断进行,可以研究这些物流,以寻找最佳方法。实施耐受树突状细胞治疗以促进临床移植耐受的科学依据是强有力的。在将耐受树突状细胞应用于临床器官移植之前,评估技术和治疗学方面的问题是重要的下一步。